Media

FeaturesJune 03, 2021

Growing at Scale

Behavioral Healthcare Executive covers our fiscal Q3 earnings report, detailing growth and forecasted clinic visits.

FeaturesJune 01, 2021

More Than Just a Treatment for Depression

Novamind CMO Reid Robison speaks to the Toronto Sun about why ketamine is a game changer for treating eating disorders.

FeaturesMay 31, 2021

Laying the Groundwork for the Psychedelic Revolution

Novamind COO Pierre Bou-Mansour discusses rapid expansion, staying consistent and Novamind's ultimate goal.

FeaturesMay 13, 2021

The Future of Psychedelic Medicine

Novamind CMO Reid Robison speaks with Technology Networks about the growing interest in psychedelic medicine and what that could mean for the future of mental health.

FeaturesMay 12, 2021

Novamind is Preparing for the Psychedelic Boom

Fast Company details our plans to expand in preparation for the FDA approval of MDMA and psilocybin, and what that approval will mean for the psychedelic industry as a whole.

FeaturesMay 07, 2021

Novamind Expands Footprint of Psychedelic Clinics

Our CEO Yaron Conforti and CMO Reid Robison discuss the news of our clinic expansion and how this further develops our model for scaling across the U.S.